Skip to main content
Top
Published in: Journal of Cachexia, Sarcopenia and Muscle 3/2011

Open Access 01-09-2011 | Review

Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle

Authors: Mariantonietta Cicoira, Stefan D. Anker, Claudio Ronco

Published in: Journal of Cachexia, Sarcopenia and Muscle | Issue 3/2011

Login to get access

Abstract

Cardio-renal syndromes (CRS) are defined as disorders of the heart and kidney whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction of the other. CRS have been classified into five categories, where types 2 and 4 represent respectively chronic cardio-renal and chronic reno-cardiac syndromes. In these conditions, the chronic disorder of either the heart or kidney has been shown to induce some degree of cachexia. At the same time, cachexia has been proposed as a possible mechanism contributing to the worsening of such pathological organ cross talk. Common pathogenetic mechanisms underlie body wasting in cachectic states of different chronic heart and kidney diseases. In these circumstances, a vicious circle could arise, in which cachexia associated with either heart failure or chronic kidney disease may contribute to further damage of the other organ. In chronic CRS, activation of the immune and neuroendocrine systems contributes to the genesis of cachexia, which in turn can negatively affect the heart and kidney function. In patients with cardiac sustained activation of the immune and neuroendocrine systems and oxidative stress, renal vascular resistance can increase and therefore impair renal perfusion, leading to worsening kidney function. Similarly, in renal cachexia, increased levels of pro-inflammatory cytokines can cause progressive left ventricular systolic dysfunction, myocardial cell death, endothelial dysfunction and increased myocardial fibrosis, with consequent impairment of the chronic reno-cardiac syndrome type 4. Thus, we speculate that the occurrence of different types of chronic CRS could represent a fundamental step in the genesis of cachexia, being renal and cardiac dysfunction closely related to the occurrence of systemic disorders leading to a final common pathway. Therefore, the heart and kidney and cachexia represent a triad causing a vicious circle that increases mortality and morbidity: In such circumstances, we may plausibly talk about cardio-renal cachexia syndrome. Complex interrelations may explain the transition from CRS to cachexia and from cachexia to CRS. Identification of the exact mechanisms occurring in these conditions could potentially help in preventing and treating this deadly combination.
Literature
1.
go back to reference Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.PubMedCrossRef Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e215.PubMedCrossRef
2.
3.
go back to reference de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006;27:569–81.PubMedCrossRef de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006;27:569–81.PubMedCrossRef
4.
go back to reference Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne JR. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422–30.PubMedCrossRef Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne JR. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13:422–30.PubMedCrossRef
5.
go back to reference Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004;44:1593–600.PubMedCrossRef Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady D, Shlipak MG. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol. 2004;44:1593–600.PubMedCrossRef
6.
go back to reference Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.PubMedCrossRef Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.PubMedCrossRef
8.
go back to reference Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.PubMed Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–43.PubMed
10.
go back to reference Mak RH, Cheung W. Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol. 2006;21:1807–14.PubMedCrossRef Mak RH, Cheung W. Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol. 2006;21:1807–14.PubMedCrossRef
11.
go back to reference Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3.PubMedCrossRef Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3.PubMedCrossRef
12.
go back to reference Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. Lancet. 2003;361:1077–83.PubMedCrossRef Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting enzyme inhibitors: an observational study. Lancet. 2003;361:1077–83.PubMedCrossRef
13.
go back to reference Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med. 2008;34:957–62.PubMedCrossRef Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med. 2008;34:957–62.PubMedCrossRef
14.
go back to reference Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.PubMedCrossRef Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52:1527–39.PubMedCrossRef
15.
go back to reference Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146.PubMedCrossRef Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117:e25–e146.PubMedCrossRef
16.
go back to reference Nohria A, Hasselbad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268–74.PubMedCrossRef Nohria A, Hasselbad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol. 2008;51:1268–74.PubMedCrossRef
17.
go back to reference Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exhacerbation of Chronic Heart Failure (OPTIME-CHF). Circulation: Heart Fail. 2008;1:25–33.CrossRef Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exhacerbation of Chronic Heart Failure (OPTIME-CHF). Circulation: Heart Fail. 2008;1:25–33.CrossRef
18.
go back to reference Mullens W, Abrahams Z, Francis GS, Soko G, Taylo DO, Starling RG, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–696.PubMedCrossRef Mullens W, Abrahams Z, Francis GS, Soko G, Taylo DO, Starling RG, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–696.PubMedCrossRef
19.
go back to reference Berl T, Henrich W. Kidney–heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1:8–18.PubMedCrossRef Berl T, Henrich W. Kidney–heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1:8–18.PubMedCrossRef
20.
go back to reference Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–9.PubMedCrossRef Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064–9.PubMedCrossRef
21.
22.
go back to reference Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.PubMedCrossRef Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–8.PubMedCrossRef
23.
go back to reference Blake P, Hasegawa Y, Khosla MC, Fouad-Tarazi F, Satura N, Paganini EP. Isolation of ‘myocardial depressant factor(s)’ from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J. 1996;42:M911–5.PubMedCrossRef Blake P, Hasegawa Y, Khosla MC, Fouad-Tarazi F, Satura N, Paganini EP. Isolation of ‘myocardial depressant factor(s)’ from the ultrafiltrate of heart failure patients with acute renal failure. ASAIO J. 1996;42:M911–5.PubMedCrossRef
24.
go back to reference Brady JP, Hasbargen JA. A review of the effects of correction of acidosis on nutrition in dialysis patients. Semin Dial. 2000;13:252–5.PubMedCrossRef Brady JP, Hasbargen JA. A review of the effects of correction of acidosis on nutrition in dialysis patients. Semin Dial. 2000;13:252–5.PubMedCrossRef
25.
26.
go back to reference Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14:1549–58.PubMedCrossRef Kelly KJ. Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol. 2003;14:1549–58.PubMedCrossRef
27.
go back to reference Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–9.PubMedCrossRef Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32:S112–9.PubMedCrossRef
28.
go back to reference Go AS, Chertow GM, Fan D, McCulloch E, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef Go AS, Chertow GM, Fan D, McCulloch E, Hsu CY. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef
29.
go back to reference McCollough PA. Why is chronic kidney disease the ‘spoiler’ for cardiovascular outcomes? J Am Coll Cardiol. 2003;41:725–8.CrossRef McCollough PA. Why is chronic kidney disease the ‘spoiler’ for cardiovascular outcomes? J Am Coll Cardiol. 2003;41:725–8.CrossRef
30.
go back to reference Parfrey PS, Foley RN, Harnett JD, Kent CM, Muraay DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11:1277–85.PubMed Parfrey PS, Foley RN, Harnett JD, Kent CM, Muraay DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant. 1996;11:1277–85.PubMed
31.
go back to reference Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18:629–36.PubMedCrossRef Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18:629–36.PubMedCrossRef
32.
go back to reference Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18:1307–15.PubMedCrossRef Kottgen A, Russell SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18:1307–15.PubMedCrossRef
33.
go back to reference Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.PubMedCrossRef Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164:659–63.PubMedCrossRef
34.
go back to reference Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034–47.PubMedCrossRef Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006;17:2034–47.PubMedCrossRef
35.
go back to reference Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity and outcome. J Am Soc Nephrol. 2003;14:1022–30.PubMedCrossRef Hoste EA, Lameire NH, Vanholder RC, Benoit DD, Decruyenaere JM, Colardyn FA. Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity and outcome. J Am Soc Nephrol. 2003;14:1022–30.PubMedCrossRef
36.
go back to reference Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP Study. Crit Care Med. 2006;34:344–53.PubMedCrossRef Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: results of the SOAP Study. Crit Care Med. 2006;34:344–53.PubMedCrossRef
37.
go back to reference Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med. 1999;27:1775–80.PubMedCrossRef Turner A, Tsamitros M, Bellomo R. Myocardial cell injury in septic shock. Crit Care Med. 1999;27:1775–80.PubMedCrossRef
39.
go back to reference Bozkurt B, Kribbs SB, Clubb Jr FJ, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumour necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;98:149–56. Bozkurt B, Kribbs SB, Clubb Jr FJ, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumour necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;98:149–56.
40.
go back to reference Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1989;63:709–13.PubMedCrossRef Carr JG, Stevenson LW, Walden JA, Heber D. Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1989;63:709–13.PubMedCrossRef
41.
go back to reference Freeman LM, Roubenoff R. The nutritional implications of cardiac cachexia. Nutr Review. 1994;52:340–7.CrossRef Freeman LM, Roubenoff R. The nutritional implications of cardiac cachexia. Nutr Review. 1994;52:340–7.CrossRef
42.
go back to reference Evans WJ, Morley JE, Argilès J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef Evans WJ, Morley JE, Argilès J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793–9.PubMedCrossRef
43.
go back to reference Kalanthar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet–gene interaction. Hemodyalisis Int. 2006;10:315–25.CrossRef Kalanthar-Zadeh K, Balakrishnan VS. The kidney disease wasting: inflammation, oxidative stress, and diet–gene interaction. Hemodyalisis Int. 2006;10:315–25.CrossRef
44.
go back to reference Kalanthar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition–inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42:864–81.CrossRef Kalanthar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition–inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42:864–81.CrossRef
45.
go back to reference Pecoits-Filho R, Nordfors L, Lindholm B, Hoff CM, Schalling M, Stenvinkel P. Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. Kidney Int Suppl. 2003;84:S162–7.PubMedCrossRef Pecoits-Filho R, Nordfors L, Lindholm B, Hoff CM, Schalling M, Stenvinkel P. Genetic approaches in the clinical investigation of complex disorders: malnutrition, inflammation, and atherosclerosis (MIA) as a prototype. Kidney Int Suppl. 2003;84:S162–7.PubMedCrossRef
46.
go back to reference Herselman M, Esau N, Kruger JM, Labadarios D, Moosa MR. Relationship between body mass index and mortality in adults on maintenance hemodialysis: a systematic review. J Ren Nutr. 2010;20:281–92.PubMedCrossRef Herselman M, Esau N, Kruger JM, Labadarios D, Moosa MR. Relationship between body mass index and mortality in adults on maintenance hemodialysis: a systematic review. J Ren Nutr. 2010;20:281–92.PubMedCrossRef
47.
go back to reference Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial. 2007;20:566–9.PubMedCrossRef Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial. 2007;20:566–9.PubMedCrossRef
48.
go back to reference Obermayr RP, Temml C, Gutjahr G, Kainz A, Klauser-Braun R, Fugger R, et al. Body mass index modifies the risk of cardiovascular death in proteinuric chronic kidney disease. Nephrol Dial Transplant. 2009;24:2421–8.PubMedCrossRef Obermayr RP, Temml C, Gutjahr G, Kainz A, Klauser-Braun R, Fugger R, et al. Body mass index modifies the risk of cardiovascular death in proteinuric chronic kidney disease. Nephrol Dial Transplant. 2009;24:2421–8.PubMedCrossRef
49.
go back to reference Braunwald E. Clinical manifestation of heart failure. In: Braunwald E, editor. Heart disease. A textbook of cardiovascular medicine, vol. 1. Philadelphia: Saunders; 1984. p. 499. Braunwald E. Clinical manifestation of heart failure. In: Braunwald E, editor. Heart disease. A textbook of cardiovascular medicine, vol. 1. Philadelphia: Saunders; 1984. p. 499.
50.
go back to reference MacGowan G, Mann D, Kormos R, Feldman A, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 1997;79:1128–31.PubMedCrossRef MacGowan G, Mann D, Kormos R, Feldman A, Murali S. Circulating interleukin-6 in severe heart failure. Am J Cardiol. 1997;79:1128–31.PubMedCrossRef
51.
go back to reference Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res. 1997;81:187–95.PubMed Kapadia SR, Oral H, Lee J, Nakano M, Taffet GE, Mann DL. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res. 1997;81:187–95.PubMed
52.
go back to reference Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–42.PubMedCrossRef Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838–42.PubMedCrossRef
53.
go back to reference Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–41.PubMedCrossRef Levine B, Kalman J, Mayer L, Fillit H, Packer M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236–41.PubMedCrossRef
54.
go back to reference Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J. 1993;70:141–3.PubMedCrossRef Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J. 1993;70:141–3.PubMedCrossRef
55.
go back to reference Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–11.PubMed Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–11.PubMed
56.
go back to reference Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–34.PubMed Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526–34.PubMed
57.
go back to reference Rauchhaus M, Doehner W, Francio DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–7.PubMed Rauchhaus M, Doehner W, Francio DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102:3060–7.PubMed
58.
go back to reference Bozkurt B, Kribbs S, Clubb Jr FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–91.PubMed Bozkurt B, Kribbs S, Clubb Jr FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97:1382–91.PubMed
59.
go back to reference Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes; involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854–65.PubMedCrossRef Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes; involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest. 1996;98:2854–65.PubMedCrossRef
60.
go back to reference Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387–9.PubMedCrossRef Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387–9.PubMedCrossRef
61.
go back to reference Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001;15:80–6.PubMedCrossRef Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine. 2001;15:80–6.PubMedCrossRef
62.
go back to reference Anker SD, Ponikowski P, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683–93.PubMedCrossRef Anker SD, Ponikowski P, Clark AL, Leyva F, Rauchhaus M, Kemp M, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683–93.PubMedCrossRef
63.
go back to reference Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205–9.PubMed Yoshizumi M, Perrella MA, Burnett JC, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res. 1993;73:205–9.PubMed
64.
go back to reference Anker SD, Volterrani M, Egerer KR, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. Q J Med. 1998;91:199–203. Anker SD, Volterrani M, Egerer KR, et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. Q J Med. 1998;91:199–203.
65.
go back to reference Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859–70.PubMedCrossRef Kajstura J, Cigola E, Malhotra A, et al. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859–70.PubMedCrossRef
66.
go back to reference Obisesan TO, Toth MJ, Yki-Jarvinen H. Free-fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol. 1996;77:1250–2.PubMedCrossRef Obisesan TO, Toth MJ, Yki-Jarvinen H. Free-fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol. 1996;77:1250–2.PubMedCrossRef
67.
go back to reference Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299–305.PubMedCrossRef Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation. 1989;80:299–305.PubMedCrossRef
68.
go back to reference Colao A. The GH–IGF-I axis and the cardiovascular system: clinical implication. Clin Endocrinol. 2008;69:347–58.CrossRef Colao A. The GH–IGF-I axis and the cardiovascular system: clinical implication. Clin Endocrinol. 2008;69:347–58.CrossRef
69.
go back to reference Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1997;18:259–69.PubMed Anker SD, Swan JW, Volterrani M, et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J. 1997;18:259–69.PubMed
70.
go back to reference Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 1994;72:S36–9.PubMedCrossRef Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J. 1994;72:S36–9.PubMedCrossRef
71.
go back to reference Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zamboni M, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response to exercise in chronic heart failure patients. J Am Coll Cardiol. 2001;37:1808–12.PubMedCrossRef Cicoira M, Zanolla L, Franceschini L, Rossi A, Golia G, Zamboni M, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response to exercise in chronic heart failure patients. J Am Coll Cardiol. 2001;37:1808–12.PubMedCrossRef
72.
go back to reference Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski P, Poole-Wilson PA, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997;30:1758–64.PubMedCrossRef Harrington D, Anker SD, Chua TP, Webb-Peploe KM, Ponikowski P, Poole-Wilson PA, et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol. 1997;30:1758–64.PubMedCrossRef
73.
go back to reference Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.PubMedCrossRef Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.PubMedCrossRef
74.
go back to reference Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–7.PubMedCrossRef Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes. 2001;50:2540–7.PubMedCrossRef
75.
go back to reference Nagaya N, Uematsu M, Kosjima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034–8.PubMedCrossRef Nagaya N, Uematsu M, Kosjima M, Date Y, Nakazato M, Okumura H, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure. Relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034–8.PubMedCrossRef
76.
go back to reference Cicoira M, Kalra P, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003;9:219–26.PubMedCrossRef Cicoira M, Kalra P, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003;9:219–26.PubMedCrossRef
77.
go back to reference Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, Von Haehling S, Okonko DO, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46:1019–26.PubMedCrossRef Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, Von Haehling S, Okonko DO, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol. 2005;46:1019–26.PubMedCrossRef
78.
go back to reference Kopple JD. Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr. 1999;129:247S–51S.PubMed Kopple JD. Pathophysiology of protein-energy wasting in chronic renal failure. J Nutr. 1999;129:247S–51S.PubMed
79.
go back to reference Kalanthar-Zadeh K, Balakrishan VS. The kidney disease wasting: inflammation, oxidative stress, and diet–gene interaction. Hemodial Int. 2006;10:315–25.CrossRef Kalanthar-Zadeh K, Balakrishan VS. The kidney disease wasting: inflammation, oxidative stress, and diet–gene interaction. Hemodial Int. 2006;10:315–25.CrossRef
80.
go back to reference Nomenclature consensus conference: kidney disease wasting. In: Fouque D, Kalantar-Zadeh K, editors. Organizing the XIII International Congress on Metabolism and Nutrition in Renal Disease, Merida, Yucatan, Mexico; 2006. Nomenclature consensus conference: kidney disease wasting. In: Fouque D, Kalantar-Zadeh K, editors. Organizing the XIII International Congress on Metabolism and Nutrition in Renal Disease, Merida, Yucatan, Mexico; 2006.
81.
go back to reference Kalantar-Zadeh K, Block G, McAllister CJ, Humphries MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004;80:299–307.PubMed Kalantar-Zadeh K, Block G, McAllister CJ, Humphries MH, Kopple JD. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr. 2004;80:299–307.PubMed
82.
go back to reference Campbell KL, MacLaughlin HL. Unintentional weight loss is an independent predictor of mortality in a hemodialysis population. J Ren Nutr. 2010;20:414–8.PubMedCrossRef Campbell KL, MacLaughlin HL. Unintentional weight loss is an independent predictor of mortality in a hemodialysis population. J Ren Nutr. 2010;20:414–8.PubMedCrossRef
83.
go back to reference Johansen KL. Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chronic Kidney Dis. 2009;16:501–10.PubMedCrossRef Johansen KL. Anabolic and catabolic mechanisms in end-stage renal disease. Adv Chronic Kidney Dis. 2009;16:501–10.PubMedCrossRef
84.
go back to reference Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr. 2006;16:208–11.PubMedCrossRef Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr. 2006;16:208–11.PubMedCrossRef
85.
go back to reference Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int. 2007;71:146–52.PubMedCrossRef Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA. Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int. 2007;71:146–52.PubMedCrossRef
86.
go back to reference Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007;17:13–6.PubMedCrossRef Ikizler TA. Effects of glucose homeostasis on protein metabolism in patients with advanced chronic kidney disease. J Ren Nutr. 2007;17:13–6.PubMedCrossRef
87.
go back to reference Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr. 2009;19:20–4.PubMedCrossRef Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr. 2009;19:20–4.PubMedCrossRef
88.
go back to reference Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11:362–639. Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11:362–639.
89.
go back to reference Parks DA, Jacobson ED. Physiology of the splanchnic circulation. Arch Intern Med. 1985;145:1278–81.PubMedCrossRef Parks DA, Jacobson ED. Physiology of the splanchnic circulation. Arch Intern Med. 1985;145:1278–81.PubMedCrossRef
90.
go back to reference Ding J, Cagnotti LJ, Huang Q, Xu DZ, Condon MR, Deitch EA. Hypoxia combined with Escherichia coli produces irreversible gut mucosal injury characterized by increased intestinal cytokine production and DNA degradation. Shock. 2001;16:189–95.PubMedCrossRef Ding J, Cagnotti LJ, Huang Q, Xu DZ, Condon MR, Deitch EA. Hypoxia combined with Escherichia coli produces irreversible gut mucosal injury characterized by increased intestinal cytokine production and DNA degradation. Shock. 2001;16:189–95.PubMedCrossRef
92.
go back to reference Mohi-ud-din K, Bali HK, Banerjee S, Sakhuja V, Jha V. Silent myocardial ischemia and high-grade ventricular arrhythmias in patients on maintenance hemodialysis. Ren Fail. 2005;27:171–5.PubMed Mohi-ud-din K, Bali HK, Banerjee S, Sakhuja V, Jha V. Silent myocardial ischemia and high-grade ventricular arrhythmias in patients on maintenance hemodialysis. Ren Fail. 2005;27:171–5.PubMed
93.
go back to reference McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease—a new aspect of cardiovascular disease. Blood Purif. 2010;29:105–10.PubMedCrossRef McIntyre CW. Haemodialysis-induced myocardial stunning in chronic kidney disease—a new aspect of cardiovascular disease. Blood Purif. 2010;29:105–10.PubMedCrossRef
94.
go back to reference Wollert K, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95–103.PubMedCrossRef Wollert K, Drexler H. The role of interleukin-6 in the failing heart. Heart Fail Rev. 2001;6:95–103.PubMedCrossRef
95.
go back to reference Ronco C, Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev; 2011 (in press). Ronco C, Cozzolino M. Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev; 2011 (in press).
96.
go back to reference Kanzaki M, Soda K, Gin PT, Kai T, Konishi F, Kawakami M. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine. 2005;32:234–9.PubMedCrossRef Kanzaki M, Soda K, Gin PT, Kai T, Konishi F, Kawakami M. Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine. Cytokine. 2005;32:234–9.PubMedCrossRef
97.
go back to reference Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004;19:2095–100.PubMedCrossRef Perez-Fontan M, Cordido F, Rodriguez-Carmona A, Peteiro J, Garcia-Naveiro R, Garcia-Buela J. Plasma ghrelin levels in patients undergoing haemodialysis and peritoneal dialysis. Nephrol Dial Transplant. 2004;19:2095–100.PubMedCrossRef
98.
go back to reference Yoshimoto A, Mori K, Sugawara A, et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol. 2002;13:2748–52.PubMedCrossRef Yoshimoto A, Mori K, Sugawara A, et al. Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol. 2002;13:2748–52.PubMedCrossRef
99.
go back to reference Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5.PubMedCrossRef Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001;86:5992–5.PubMedCrossRef
100.
go back to reference Wu R, Dong W, Cui X, et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg. 2007;245:480–6.PubMedCrossRef Wu R, Dong W, Cui X, et al. Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg. 2007;245:480–6.PubMedCrossRef
101.
go back to reference DeBoer MD, Zhu XX, Levasseur PR, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007;148:3004–12.PubMedCrossRef DeBoer MD, Zhu XX, Levasseur PR, et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology. 2007;148:3004–12.PubMedCrossRef
102.
go back to reference Baracos VE. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care. 2002;5:237–9.PubMedCrossRef Baracos VE. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care. 2002;5:237–9.PubMedCrossRef
103.
go back to reference Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15:543–62.PubMedCrossRef Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev. 2010;15:543–62.PubMedCrossRef
104.
go back to reference von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.CrossRef von Haehling S, Morley JE, Coats AJ, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010;1:7–8.CrossRef
Metadata
Title
Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle
Authors
Mariantonietta Cicoira
Stefan D. Anker
Claudio Ronco
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Journal of Cachexia, Sarcopenia and Muscle / Issue 3/2011
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-011-0038-2

Other articles of this Issue 3/2011

Journal of Cachexia, Sarcopenia and Muscle 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine